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Abstract
Orai1 is the key subunit of the Ca
2+-release-activated 
Ca
2+ channel. Our previous report has demonstrated 
that Orai1 expression in the airway was upregulated in 
the ovalbumin (OVA)-induced allergic rhinitis (AR) 
mouse models. To observe whether inhibition of Orai1 
expression in the airway could suppress symptoms in 
a murine model of AR and to assess the impacts of this 
inhibition on the responses of local and systemic im-
munocytes, we administered recombinant lentivirus 
vectors that encoded shRNA against ORAI1 (lenti-ORAI1) 
into the nostrils of OVA-sensitized mice before the 
challenges, and analyzed its effect on allergic re-
sponses, as compared with the unsensitized mice and 
untreated AR mice. Administration of lenti-ORAI1 into 
the nasal cavity successfully infected cells in the epi-
thelial layer of the nasal mucosa, and significantly de-
creased the frequencies of sneezing and nasal rubbing 
of the mice. Protein levels of leukotriene C4, OVA-spe-
cific IgE, and IL-4 in the nasal lavage fluid and serum 
and eosinophil cation protein in the serum were also 
significantly  reduced  by  lenti-ORAI1,  as  were  the 
mRNA levels of these factors in the nasal mucosa and 
spleen. These data suggested that administration of 
lenti-ORAI1 into the nasal cavity effectively decreased 
Orai1 expression in the nasal mucosa, alleviated AR 
symptoms, and partially inhibited the hyperrespon-
siveness of the local and systemic immune cells in-
cluding T cells, B cells, mast cells and eosinophils that 
are involved in the pathogenesis of AR. 
Keywords: calcium channels; disease models, ani-
mal; lentivirus; mice; ORAI1 protein, human; rhinitis; 
RNA interference 
Introduction
Allergic rhinitis (AR) is allergic inflammation in the up-
per airway associated with the hyperresponsiveness 
of several types of immune cells. With the help of 
antigen presenting cells (APCs), an allergen trig-
gers a Th2-predominant immune response that 
leads to the generation of memory B cells that pro-
duce antigen-specific IgE. This IgE binds to mast 
cells, and subsequent exposure to the allergen 
provokes these IgE-binding mast cells to release 
inflammatory mediators, such as histamine and 
leukotriene C4 (LTC4), that induce allergic reactions. 
Eosinophilic infiltration also plays a role in persis-
tent airway inflammation and remodeling. Mainstream 
therapy for AR consists of disease control through 
the use of anti-inflammatory agents, glucocorticoid- 
based drugs, antihistamines, and antileukotrienes. 
Although these drugs relieve symptoms in most 
patients, they do not cure the underlying disease. 
Therefore, the challenge to develop safe, new ther-
apeutic agents that target the root of the patho-
genesis of AR remains.
    There is growing evidences that in cells of the 
immune system, Ca
2+ entry from the extracellular 
medium is induced by the depletion of endoplasmic 
reticulum (ER) Ca
2+ stores and mediated by speci-178    Exp. Mol. Med. Vol. 44(3), 177-190, 2012
alized store-operated Ca
2+ channels called Ca
2+-re-
lease-activated Ca
2+ (CRAC) channels (Hoth and 
Penner, 1992). The molecular composition of these 
channels and the mechanisms linking store deple-
tion to channel activation remained obscure until 
2005 when stromal interaction molecule 1 (STIM1) 
was identified as the mammalian ER Ca
2+ sensor 
(Liou et al., 2005). Orai1 was later identified as a 
key subunit of the CRAC channel pore (Prakriya et 
al., 2006). STIM1 is a single pass ER-resident pro-
tein with a Ca
2+ binding EF hand domain that faces 
the ER lumen. Ca
2+ dissociates from the EF hand 
during store depletion, which leads to STIM1 
oligomerization. The oligomers then migrate and 
form punctate-like structures below the plasma 
membrane. The oligomers bind to Orai1, which is 
diffusely distributed in the plasma membrane at 
rest, and activate it, causing formation of the chan-
nel pore. Mammalian cells express two other 
closely related homologues of Orai1, Orai2 and 
Orai3, which appear to function similarly in media-
ting store-operated Ca
2+ entry (SOCE) when co-ex-
pressed with STIM1, but their Ca
2+ currents are 2- 
to 3-fold weaker than the Ca
2+ current mediated by 
Orai1 (Mercer et al., 2006). The discovery of these 
proteins has led to rapid progress in the illumina-
tion of the molecular mechanisms of the afore-
mentioned pathway and its functions in various 
tissues. 
    The process of store-operated Ca
2+ influx is es-
sential for both the short- and long-term responses 
of immune system cells. Short-term responses in-
clude the degranulation of mast cells and the killing 
of target cells by effector cytolytic T cells, whereas 
long-term responses typically involve changes in 
gene transcription through the Ca
2+/calcineur-
in/nuclear factor of activated T cells signaling path-
way and include T- and B-cell proliferation and dif-
ferentiation (Parekh and Putney, 2005; Gwack et 
al., 2007). These responses are considered crucial 
processes in the induction and development of AR. 
    In our first study, it was revealed that Orai1 was 
expressed in murine nasal mucosa, nasal-asso-
ciated lymphoid tissue (NALT), trachea mucosa, 
and spleen and that Orai1 expression was upregu-
lated in AR mice compared to controls (Lin et al., 
2010), suggesting that the SOCE pathway may 
contribute to the pathogenic mechanisms of AR 
and could be a potential therapeutic target for the 
treatment of AR. In our subsequent study, we dem-
onstrated that the administration of 2-amino-
ethoxydiphenyl borate (2-APB), which inhibits the 
activation of CRAC, into the nostrils of AR mice 
could alleviate allergic symptoms and reduce the 
number of eosinophils that infiltrate into the nasal 
mucosa. Furthermore, the administration suppressed 
Orai1 expression in nasal mucosa and decreased 
allergic inflammatory mediators in the nasal lavage 
fluid (NLF) (Lin et al., 2011). However, 2-APB has 
been known to interfere with a variety of transport 
processes besides CRAC channels, including K
+ 
channels (Wang et al., 2002) and mitochondrial 
Ca
2+ efflux (Prakriya and Lewis, 2001). This lack of 
specificity could lead to questions about the validity 
of our results obtained with 2-APB. Furthermore, 
the temporary inhibition of CRAC channels by 
2-APB may lead to only transient inhibition of AR 
symptoms.
    Based  on  our  previous  findings,  the  present 
study was designed to observe whether inhibition 
of Orai1 expression specifically in the airway could 
suppress allergic symptoms in murine models of 
AR and how this reduced expression impacts the 
responses of local and systemic immune cells in-
cluding T cells, B cells, mast cells and eosinophils. 
We hope that the findings presented here may pro-
vide further insight on the role the SOCE pathway 
plays in the pathogenesis of AR and render some 
clues to the development of novel therapies.
Results
Transfection efficacies and Orai1 transcription in-
hibition efficacies of Lenti-Orai1 and Lenti-GFP
The transfection efficacies of recombinant lentivi-
rus vectors that encoded shRNA against ORAI1 as 
well as green fluorescent protein (GFP) (lenti-ORAI1) 
and lentivirus vectors only encoded GFP (lenti-GFP) 
were analyzed by fluorescence-activated cell sort-
ing (FACS) for GFP expressed in the transfected 
PANC cells. When the multiplicity of infection (MOI) 
is 10, the transfection efficacy of Lenti-ORAI1 is 
98.28%, and the transfection efficacy of Lenti-GFP 
is 98.75%. Orai1 transcription inhibition efficacies 
of Lenti-ORAI1 and Lenti-GFP were determined by 
measuring the Orai1 mRNA levels of control PANC 
cells, PANC cells transfected by lenti-ORAI1 and 
lenti-GFP, respectively. When the MOI is 10, the 
inhibition efficacy of Lenti-ORAI1 is 90.5%, and 
that of lenti-GFP is -1.4% (Figure 1A).
The kinetics of the inhibition efficacy of Orai1 
transcription by in vivo transfection with Lenti-Orai1
The in vivo inhibition efficacies of Lenti-ORAI1 var-
ied according to the duration of the transfetion. The 
kinetics of the inhibition efficacy were showed in 
Figure 1B. Since the inhibition efficacy reached a 
maximum in the third day after the transfection, 
which is 58.5% (Figure 1B), we choosed the timing Orai1 expression and murine allergic rhinitis    179
Figure 2. Experimental design. The mice were randomly divided into five 
groups: normal control , normal mice with Lenti-Orai1 interferenced (NLI), 
mice with allergic rhinitis (AR), AR mice with lenti-GFP interferenced 
(AR-GFP), and AR mice with lenti-Orai1 interferenced (AR-LI). The mice 
of AR, AR-GFP and AR-LI groups received ovalbumin (OVA)/aluminum 
hydroxide introperitoneal injection as sensitization on day 1, 8 and 15, 
followed with OVA intronasal challenges on day 22-29. The mice in group 
NLI and AR-LI were given the single dose of lenti-Orai1 on day 19; 
meanwhile, mice in group AR-GFP were given a single dose of lenti-GFP. 
Figure 3. GFP expression in the na-
sal mucosa. The arrowheads in-
dicate GFP expression in trans-
fected cells in the epithelial layer of 
the nasal mucosa of mice intra-
nasally administered lenti-Orai1 (F) 
or lenti-GFP (I). There was no GFP 
expression in the nasal mucosa of 
the mice in the normal control group 
and AR group (C). A, D, G: GFP. B, 
F, H: DAPI. C, F, I: Merge. Scale bar 
=5 0   μm
Figure 1. Orai1 transcription inhibition efficacies. Orai1 transcription in-
hibition efficacies of lenti-Orai1 and lenti-GFP in PANC cells (A), and the 
kinetics of the inhibition efficacy of Orai1 transcription of lenti-Orai1 in the 
mouse nasal mucosa (B). Orai1 transcription level of each sample was 
assessed by real-time RT-PCR. Each value represents mean ± SEM.
for transfecting the mice in NLI, AR-GFP and AR-LI 
groups with corresponding lentiviruses three days 
before accepting the first challenge with ovalbumin.
Administration of recombinant lentivirus to the nasal 
cavity via inhalation-driven instillation successfully 
transfected cells in the nasal mucosa
The experimental design is summerized in Figure 
2. To determine if the recombinant lentivirus was 
successfully transfected into cells in the airway, 
three mice of each group were sacrificed on the 
first day of the challenge, their nasal mucosa and 
spleens were carefully dissected and observed un-
der fluorescence microscope to determine if the 
green fluorescence of GFP was expressed in po-
tentially transfected cells. The inhalation-driven in-
stillation of lentiviruses established GFP transgene 
expression in the nasal mucosas of NLI, AR-GFP 
and AR-LI mice, while no green fluorescence was 
observed in either the normal control mice or the 
AR mice. Similar to the findings of Stocker et al 
(Stocker  et al., 2009), the cells expressing GFP 
were mainly dispersed within the anterior regions 180    Exp. Mol. Med. Vol. 44(3), 177-190, 2012
Figure 4. The mRNA and protein expression of Orai1. Orai1 transcript 
levels in the nasal mucosa (A) and spleen (B) of mice in each group were 
assessed by real-time RT-PCR. Each value represents mean ± SEM. 
*P ＜ 0.05 vs. AR group; ***P ＜ 0.001 vs. AR group; 
###P ＜ 0.001 vs. 
normal control group. Orai1 expression levels in the nasal mucosa (C) 
and spleen (D) of the mice were determined by Western blotting.
Figure  5. Orai1 distribution. 
Arrowheads indicate immunor-
eactivity for Orai1 in cells in normal 
controls (A, D, G), allergic rhinitis 
(AR) mice (B, E, H), and lentivirus 
intervention (AR-LI) mice (C, F, I) in 
the nasal mucosa (A-C), NALT 
(D-F), and spleen (G-I). EP, epi-
thelial layer of nasal mucosa; LP, 
lamina propria of the nasal mucosa; 
GC, germinal center; MZ, marginal 
zone. Scale bar = 50 μm for A-C, 
20 μm for D-I.
of the epithelial layer in the treated nasal airways 
(Figure 3). The spleen of each mouse was also ex-
amined, and no green fluorescence signal was ob-
served in any spleen, including the spleens of the 
NLI, AR-GFP and AR-LI groups. This implies that 
administration of the lentivirus vector through the 
nostrils did not lead to the transfection of 
splenocytes.
Administration of lenti-ORAI1 siRNA downregulated 
Orai1 expression in the nasal mucosa and spleen 
The extracted Orai1 mRNA from the nasal mucosa 
and spleens of the mice were evaluated by re-
al-time RT-PCR. Orai1 mRNA levels in the nasal 
mucosa and spleen were upregulated in AR mice 
compared to normal controls (P ＜ 0.05, and P ＜
0.05, respectively; Figures 4A and 4B). In addition, 
lenti-ORAI1 treatment significantly reduced the lev-
els of Orai1 mRNA in the nasal mucosa of AR-LI 
mice compared to the AR group (P ＜ 0.001, AR-LI 
vs. AR; Figure 4A), as well as the levels in the NLI 
mice compared to the normal ones (P ＜ 0.001, 
NLI vs. normal; Figure 4A). The treatment of the 
sensitized and challenged mice with lenti-GFP 
didn’t change their Orai1 mRNA levels in the nasal 
mucosa compared to AR mice (P ＞0.05, Figure 
4A). Both administration of lenti-ORAI1 and len-
ti-GFP to the nasal cavity had no effect on Orai1 
mRNA levels in the spleen (P ＞0.05, P ＞0.05, P
＞0.05, NLI vs. normal, AR-GFP vs. AR, AR-LI vs. 
AR, respectively; Figure 4B), which was consistent 
with our observation that the splenocytes had not 
been transfected by the lentiviruses. 
    The proteins extracted from the nasal mucosa 
and spleens of the mice were evaluated by Western Orai1 expression and murine allergic rhinitis    181
No.
Nasal mucosa NALT Spleen
EC LC IC IC
Normal controls
    1 + + +/- +
    2 - - - +
    3 - - - +
    4 + + +/- +
    5 - - - +
    6 - - - +
AR group
    7 +++ +++ ++ ++
    8 +++ +++ ++ ++
    9 + + + + + ++ ++ + +
  10 +++ +++ ++ ++
  11 +++ +++ ++ +++
  12 +++ +++ ++ ++
LI group
  1 3 -+++
  1 4 + + ++ ++ +
  1 5 -+++
  1 6 -+++
  17 - + + ++
  18 + ++ + ++
The numbers 1-18 each represent an individual mouse; EC, cells in the 
epithelial layer of the nasal mucosa; LC, cells in the lamina propria of the 
nasal mucosa; IC, immune cells; -, the absence of positivity; +, weakly 
positive; ++, definitely positive; +++, strongly positive.
Table 1. Immunoreactivity to Orai1 in the nasal mucosa, NALT, and
spleen
             Group Normal NLI AR AR-GFP AR-LI
Epithelial cells (× 10
4/ml) 0.77 ± 0.26* 0.55 ± 0.20   6.89 ± 1.92   7.02 ± 2.00 1.30 ± 0.54*
Lymphocytes (× 10
4/ml) 2.29 ± 0.55* 1.99 ± 0.47 10.37 ± 1.99 10.89 ± 2.97 3.35 ± 1.08*
Eosinophils (× 10
3/ml) 0.36 ± 0.11* 0.31 ± 0.15   9.18 ± 2.27   9.14 ± 2.41 1.22 ± 0.57*
Neutrophils (× 10
4/ml) 0.51 ± 0.13* 0.44 ± 0.14   4.41 ± 1.39   3.42 ± 0.59 1.22 ± 0.49*
Total cells (× 10
4/ml) 3.60 ± 0.89* 3.00 ± 0.82 22.60 ± 4.83 22.25 ± 5.50 6.00 ± 2.00*
This table represents the mean and the standard deviation of determinations.
*Statistical significance was noted as compared with AR mice, P ＜ 0.05.
Table 2. Total cell number and diffrrential cell numbers in NLF of the mice
Figure 6. Nasal allergic symptoms. The number of sneezes (A) and na-
sal rubbing episodes (B) were determined for 10 min immediately follow-
ing the final challenge for the mice. Each value represents the mean ±
SEM of each group. *P ＜ 0.05; ***P ＜ 0.001 vs. the AR group.
Blotting. The results from the nasal mucosa showed 
a much higher level of Orai1 protein expression in 
the AR group compared to the normal group and 
an apparently decreased level of Orai1 in the 
AR-LI group compared to the AR group (Figure 
4C). Both of the expression of the normal mice and 
NLI mice are too low to detect. The Orai1 ex-
pression level of the mice in GFP group was sim-
ilar to that of the AR mice. The results in the spleen 
were similar to that in the nasal mucosa (Figure 
4D). 
The distribution of Orai1 changed after lenti-ORAI1 
siRNA administration
Immunohistochemical staining of Orai1 was per-
formed to demonstrate its distribution in murine na-
sal mucosa, NALT, and spleen. Orai1 was localized 
primarily in the plasma membrane of cells in these 
tissues. In the nasal mucosa of AR mice, Orai1 
was located in cells in the epithelial layer and the 
ductal epitheliums of the submucosal glands, while 
it was barely detectable in normal mice (Figures 5A 
and 5B). In AR-LI mice, compared to the AR group, 
a marked reduction of Orai1 was observed in cells 
in the epithelial layer of the nasal mucosa and a 
less robust, but still definitive reduction was ob-
served in cells in the lamina propria (Figure 5C). 
Furthermore, Orai1 protein was localized in the 
plasma membrane of immunocytes in the NALT 
and spleen (Figures 5E and 5H), and its im-
munostaining was more intense in the AR group 
than the AR-LI group (Figures 5F and 5I). The im-
munostaining was hard to detect in the NALT of the 
normal control group, and was only weakly positive 
in the marginal zones of the spleens of normal 
group (Figures 5D and 5G). On the other hand, al-
though the Orai1 expression in the lymphocytes re-
siding in the marginal zones in the spleens of 
AR-LI mice was still distinctly positive, its ex-
pression in the cells residing in the germinal cen-182    Exp. Mol. Med. Vol. 44(3), 177-190, 2012
Figure 7. ELISA analysis of LTC4, ECP, OVA-IgE and IL-4 in the NLF 
(A-D, respectively) and serum (E-H, respectively) of the mice. Each value 
represents the mean ± SEM of each group. *P ＜ 0.05; ***P ＜ 0.001 
vs. the AR group.
ters of these mice was much lower than that in the 
AR mice (Figure 5I). The detailed distribution of 
Orai1 immunopositive cells is presented in Table 1. 
Downregulation of Orai1 expression in the airway 
alleviated symptoms of allergic rhinitis in mice
To examine whether the downregulation of Orai1 
expression in the airway in vivo had protective ef-
fects on allergic rhinitis, the number of sneezes 
was recorded after the last OVA challenge. The AR 
group showed an apparent increase in the number 
of sneezes (65.60 ± 4.88 counts/10 min) com-
pared to the normal control group that had only re-
ceived one dose of challenge on day 29 (1.70 ±
0.42 counts/10 min). The average sneeze count of 
AR-LI mice was 16.20 ± 3.28 counts/10 min, and 
this was significantly less than that of AR mice (P
＜ 0.001; Figure 6A). At the same time, the number 
of nasal rubbings was recorded by another 
observer. Similarly, AR mice showed an obvious in-
crease in the number of nasal rubbings (115.00 ±
6.24 counts/10 min) compared to the normal mice 
(7.30 ± 1.25 counts/10 min), and AR-LI mice had 
significantly less nasal rubbings (27.90 ± 2.12 
counts/10 min) than AR mice (P ＜ 0.001; Figure 
6B). However, the administration of lenti-GFP 
could neither decrease the number of sneezing nor 
the number of nasal rubbings. These results clearly 
indicated that the downregulation of Orai1 ex-
pression in the airway by a single intranasal admin-
istration of lenti-ORAI1 alleviated allergic symp-
toms in mice.
Total and differential inflammatory cell numbers in 
NLF
Total and differential cell number were counted in 
NLF obtained from each mice (Table 2). The total 
cell number in the NLF of AR mice was sig-
nificantly greater than that of normal mice. The 
numbers of epithelial cells, lymphocytes, eosino-
phils and neutrophils in NLF were all significantly 
greater in AR mice than in normal mice. Most pre-
dominant difference was observed in the number 
of eosinophils. The total and differential cell num-
bers, especially the number of eosinophils in the 
NLF of AR-LI mice were all decreased compared 
to AR mice. 
Levels of allergic inflammatory cytokines and im-
munoglobulins in the NLF and serum decreased after 
treatment with lenti-ORAI1 
We examined LTC4, eosinophil cation protein 
(ECP), ovalbumin-specific IgE (OVA-IgE), and IL-4 
levels, which represent the function of mast cells, 
eosinophils, B cells and Th2 cells respectively, in 
the NLF and serum of the mice. The NLF and se-
rum levels of LTC4, ECP, OVA-IgE, and IL-4 of AR 
mice were all elevated compared to those of the 
normal group (all P ＜ 0.001; Figure 7). The NLF 
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Figure 8. Real-time RT-PCR analysis of mRNA levels of LTC4S, EAR3, 
germline Cε, and IL-4 in the nasal mucosa (A-D, respectively) and 
spleen (E-H, respectively) of the mice. Each value represents the mean
± SEM of each group. *P ＜ 0.05; ***P ＜ 0.001 vs. the AR group; 
#P
＜ 0.05 vs. normal control group.
Figure 9. Protein expression of IL-33, IL-17E and TSLP. Expression lev-
els of IL-33, IL-17E and TSLP in the nasal mucosa of the mice in each 
group were determined by Western blotting.
group were significantly reduced compared to 
those of AR mice (P ＜ 0.001, P ＜ 0.05, and P ＜
0.001, respectively; Figures 7A, 7C and 7D). 
However, there was not a significant difference be-
tween the AR-LI and AR groups in the NLF level of 
ECP (P ＞0.05; Figure 7B). The serum levels of 
LTC, ECP, OVA-IgE, and IL-4 in AR-LI mice were 
all significantly reduced compared to those in the 
AR group (P ＜ 0.001, P ＜ 0.05, P ＜ 0.001, and P
＜ 0.001, respectively; Figure 7E-7H). These re-
sults showed that suppression of Orai1 expression 
in the nasal mucosa inhibited both local and sys-
temic allergic responses.
Lenti-ORAI1 inhibited the induction of leukotriene C4 
synthase (LTC4S), eosinophil-associated, ribonu-
clease A family, member 3 (EAR3), IL-4, and Germline 
Cε transcripts in the nasal mucosa and spleen in 
AR-LI mice
To investigate the effect of the intranasal admin-
istration of lenti-ORAI1 on mRNA levels of LTC4S, 
EAR3, the germline C transcript, and IL-4 in the 
nasal mucosa and in spleen, we measured levels 
of these transcripts by real-time RT-PCR. In the AR 
mice, compared to normal controls, there were in-
creases in all four transcripts in both the nasal mu-
cosa and spleen (all P ＜ 0.001; Figure 8). The ad-
ministration of lenti-ORAI1 resulted in a reduction 
of these transcripts in the nasal mucosas (LTC4S, 
P ＜ 0.001; EAR3, P ＜ 0.05; germline C transcript, 
P ＜ 0.001; IL-4, P ＜ 0.05; all vs. the AR group; 
Figures 8A-8D) and the spleens (LTC4S, P ＜
0.001; EAR3, P ＜ 0.05; germline C transcript, P ＜
0.05; IL-4, P ＜ 0.05; all vs. the AR group; Figures 
8E-8H) in AR-LI mice compared to AR mice, but 
have no influence on NLI mice compared to normal 
mice. These findings suggested that RNA interfer-
ence of Orai1 in the nasal mucosa limited allergic 
responses in the nasal mucosa and spleen.
Downregulation of Orai1 expression reduced the ex-
pression of IL-33 and thymic stromal lymphopoietin 
(TSLP) in AR-LI mice
The expressions of IL-33, IL-17E and TSLP in the 
nasal mucosa of the mice were evaluated by 
Western Blotting. The results showed higher levels 
of IL-33, TSLP and IL-17E expression in the AR 184    Exp. Mol. Med. Vol. 44(3), 177-190, 2012
group compared to the normal group and slightly 
decreased levels of IL-33 and TSLP in the AR-LI 
group compared to the AR group (Figure 9). 
However, the level of IL-17E in AR-LI mice was not 
influenced by the administration of lenti-ORAI1 
compared to AR mice. The IL-33, IL-17E, and 
TSLP expression levels of the AR-GFP mice were 
similar to that of the AR mice. 
Discussion
Ca
2+ signals are vital in the function of many cell 
types of the immune system, including T cells, B 
cells, NK cells, mast cells, dendritic cells, and mac-
rophages, and they control cell functions as di-
verse as differentiation, proliferation, gene ex-
pression, cell motility, and the secretion of vesicles 
that contain cytokines, cytotoxic proteins, and/or 
proinflammatory proteins (Feske, 2007; Gwack et 
al., 2007). In immune cells, Ca
2+ signaling results 
from the engagement of antigen receptors at the 
cell surface. Therefore, they directly determine the 
intensity of the immune response triggered by an 
antigen (Feske, 2009). These responses are con-
sidered crucial processes in the induction and de-
velopment of AR. 
    We administered 2-APB into the nostrils of AR 
mice to partially block the activation of CRAC 
channels, and this successfully limited the in-
flammation (Lin et al., 2011). However, as men-
tioned above, 2-APB has been known to interfere 
with a variety of transport processes besides 
CRAC channels. In addition, 2-APB is hydrosoluble. 
Thus, it can enter into the bloodstream and be dis-
persed via the circulatory system. This may lead to 
the inhibition of CRAC channels in tissues outside 
the airway, causing unexpected side effects such 
as global muscular hypotonia (Vig et al., 2006) (we 
also observed that after the administration of 
2-APB, mice exhibited transient delayed ambula-
tion and slightly reduced muscle strength that last-
ed for a few seconds to 1 min; unpublished data), 
chronic pulmonary disease, and congenital 
myopathy. Further, 2-APB administration only led 
to a transient remission of AR symptoms.
    The  use  of  ORAI1 knock-in mice might better 
demonstrate the role that SOCE plays in the patho-
genesis of AR. However, the absence of ORAI1 in 
mice can lead to the compromise of mast cell (Vig 
et al., 2008), B-cell, and T-cell function (Gwack et 
al., 2008), all of which are indispensable in the 
process of sensitization. Furthermore, mice that 
lack ORAI1 have a short postnatal lifespan (with 
certain variations due to the method and genetic 
background used for gene targeting). 
    Therefore, we turned to the method of RNA in-
terference (RNAi), a method often used in gene 
therapy. RNAi is the docking of specific small RNA 
molecules with the complementary mRNA. This 
leads to the formation of a RNA-induced silencing 
complex that leads to mRNA degradation and the 
resulting inhibition of translation (Popescu and 
Popescu, 2007). RNAi could be a more efficient 
method to block the function of CRAC channels 
than agents that target Orai1 because multiple 
copies of Orai1 protein are translated from one 
mRNA molecule. Lentiviral gene vectors are often 
used in RNAi in vivo because of their ability to in-
tegrate their transgene into host-cell chromo-
somes, resulting in longer lasting genetic alteration 
(Cockrell and Kafri, 2007). Respiratory epithelial 
cells are either slowly dividing or terminally differ-
entiated, rendering them good candidates to ach-
ieve prolonged gene silencing, while inflammatory 
cells are also important targets (Maes et al., 2011). 
In addition, gene therapy can occur by the direct 
delivery of gene transfer vectors to the nasal 
cavity. This allows for a general airway distribution 
and the potential targeting of different cell types 
(but mainly epithelial cells) (Griesenbach and 
Alton, 2009; Gill et al., 2010). We delivered a sin-
gle dose of a human immunodeficiency virus type 
I-derived lentiviral vector that contained synthe-
sized anti-ORAI1 shRNA sequences and the GFP 
gene into the nasal cavity of mice after pre-treat-
ment of the airway with LPC. LPC is a naturally oc-
curring airway surfactant component (Chen et al., 
2006), and it can provide the vector deeper access 
through the transient permeabilization of epithelial 
tight junctions (Koehler et al., 2005). Minimal in 
vivo toxicity has been observed for LPC at concen-
trations that provide strong enhancement of in vivo 
airway gene transduction into both the surface 
cells and the deeper cells of the epithelial layer 
(where the progenitor cell pools reside) (Kremer et 
al., 2007). 
    Our observation indicated that a single dose of 
ORAI1 RNAi lentivirus can achieve a lasting in-
hibition of Orai1 expression in the nasal mucosa, 
which could lead to a steady blocking effect on 
SOCE, and it could reach the peak of the inhibition 
efficacy three days after the administration of the 
lentiviruses. The dose of the recombinant lentivirus 
we chose to administer was decided based on a 
previous study where we assessed its effect on the 
expression of Orai1 using Western blotting. In that 
study, we administered 20 or 40 μl of the lentivirus 
at a titer of 1 × 10
8，5 × 10
8, or 1 × 10
9 tu/ml and 
found that the downregulation of Orai1 was most 
apparent when a titer of 1 × 10
9 tu/ml was used, 
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data). This may be the result of “excess” lentivirus 
entering into the lower airway. However, the block-
ing effect might be partial. Only a small percentage 
of the cells in the epithelial layer were transfected, 
and the AR-LI mice still had greater Orai1 ex-
pression in the nasal mucosa than the normal con-
trols, suggesting that the gene intervention did not 
lead to the complete absence of CRAC channel 
function and the resulting complete inability to 
mount an effective immune response to non-aller-
gens (such as pathogens).
        The splenocytes were not found to be trans-
fected, and the Orai1 mRNA levels in the spleen 
did not significantly change after lenti-ORAI1 
treatment. Therefore, it is reasonable to deduce 
that the locally delivered lenti-ORAI1 probably did 
not (and cannot) enter into the bloodstream and 
did not affect SOCE in other systems. If this is true, 
it would practically guarantee that the use of len-
ti-ORAI1 would have a much lower risk of causing 
side effects than 2-APB. In agreement with this, we 
did not observe any delayed ambulation or re-
duced muscle strength after the administration of 
lenti-ORAI1. However, we did find that Orai1 ex-
pression was still slightly decreased in the spleen. 
This finding cannot be explained based on the oth-
er findings of this study, but it can be hypothesized 
that this alteration was secondary to the reduction 
of Orai1 expression in the nasal mucosa. 
    The allergic symptoms were alleviated after the 
local interference of Orai1 expression, and the lym-
phocytes, neutrophils, eosinophils and epithelial 
cells in the NLF were also reduced. This may be 
due to a decrease of the intensity of the responses 
by the transfected epithelial cells. The cells that re-
side in the epithelial layer of the nasal mucosa of 
mice with AR include nasal epithelial cells (NECs), 
and some infiltrating dendritic cells, mast cells, T 
cells, B cells, and eosinophils. SOCE and ICRAC 
have been observed in all of these cell types ex-
cept eosinophils (Hoth and Penner, 1992; Zweifach 
and Lewis, 1993; Hsu et al., 2001; Liu et al., 2005). 
In the present study, we found that the lenti-ORAI1 
can only transfected the cells in the anterior re-
gions of the epithelial layer of the nasal mucosa. 
The timing of transfection with lenti-ORAI1 we 
choose was three days before the first challenge. 
Using the immunofluorescence method, we didn’t 
observe the infiltration of T cells, B cells, mast cells 
and eosinophils in the epithelial layer of the nasal 
mucosa when the mice received three times of 
sensitization but were not challenged yet. Therefore, 
most of the transfected cells were NECs, instead of 
the inflammatory cells we hypothesized before.
    In  NECs,  SOCE  is  the  predominant  cause  of 
Ca
2+ influx. It can regulate secretion by NECs, both 
the discharge of proteins and the regulation of the 
transepithelial secretion of salts and water (Parekh 
and Putney, 2005). NECs from patients with AR 
could amplify the allergic reaction and contribute to 
ongoing allergic inflammation via their capacity to 
act as APCs through the increased expression of 
HLA-DR and CD86 (Takizawa et al., 2007). They 
can also attract and activate DCs for the initiation 
of Th2 immune responses (Hammad and Lambrecht, 
2008) and help shape Th2 responses by directly 
attracting and activating Th2 cells, natural killer T 
cells, eosinophils, basophils, and mast cells. NECs 
are in direct contact with the inhalant allergens; 
due to the presence of memory T cells in the epi-
thelial layer and the capacity of NECs to induce the 
antigen-specific proliferation of T cells, NECs may 
play an even more important role in allergic in-
flammation than what has been demonstrated 
(Takizawa  et al., 2007). The cytokines IL-17E, 
IL-33, and TSLP lie upstream of the classical Th2 
cytokines, and the fact that they are all produced 
by ECs provides evidence at the molecular level 
for how ECs can directly impact Th2 immunity (Liu 
et al., 2007; Saenz et al., 2008). In our study, lev-
els of IL-33 and TSLP expression in the nasal mu-
cosa were both decreased while there was no dis-
tinct reduction of IL-17E expression level after the 
Orai1 expression was downregulated. IL-33 is ini-
tially produced by epithelium at the mucosal surfa-
ces in response to challenges, including microflora, 
allergens, and certain pathogens, and subsequently 
amplified by other tissue-resident cells and in-
flammatory cells during inflammatory responses 
(Bulek et al., 2010). IL-33 has been shown to have 
a critical function in the initiation and propagation 
of Th2 immune responses. in vivo, including in-
creased production of Th2 cytokines IL-4, IL-5, 
IL-13, eosinophilia, and pathological changes in 
mucosal tissues (Schmitz et al., 2005). Recent 
studies showed that treatment with anti-IL-33 in 
model of allergic asthma significantly reduced se-
rum IgE, the numbers of eosinophils and lympho-
cytes, and concentrations of IL-4, IL-5, and IL-13 in 
bronchoalveolar lavage fluid (Liu et al., 2009). 
IL-33 could also increased the survival of eosino-
phils and induced their superoxide anion pro-
duction and degranulation. IL-33 induced pro-
duction of IL-8 and enhanced the viability and ad-
hesiveness of eosinophils (Cherry et al., 2008). 
Moreover, mast cells are responsive to IL-33. IL-33 
was able to stimulate mast cells to produce pro-in-
flammatory mediators, cytokines, and chemokines 
including IL-4, IL-13, IL-1b, GM-CSF, TNF-a, 
MCP-1, IL-8, and IL-6 (Moulin et al., 2007). IL-33 
enhanced the maturation and survival of mast cells 
(Allakhverdi et al., 2007). EC-derived TSLP directly 186    Exp. Mol. Med. Vol. 44(3), 177-190, 2012
activates DCs to generate Th2 permissive micro-
environment. TSLP induces the expression of che-
mokines thymus and activation regulated chemo-
kine and macrophage-derived chemokine in 
CD11c
+ DC subset. Those chemokines are ligands 
for CCR4, which is predominantly found on Th2-type 
lymphocytes. Furthermore, TSLP also induced the 
expression of OX40 ligand on DCs, which is re-
quired for inflammatory Th2 differentiation. 
TSLP-activated DCs direct naive Th cells to pro-
duce the pro-inflammatory cytokines including IL-4, 
IL-5, IL-13, and TNFa, but not IL-10 and IFNγ. Mast 
cells also express TSLPR and respond to TSLP by 
producing high levels of Th2 cytokines (Soumelis 
et al., 2002; Rimoldi et al., 2005).
    Therefore,  although  the  lenti-Orai1  could  only 
transfected and hamper the transcripiton of Orai1 
in NECs, through inhibiting the secrection of IL-33 
and TSLP by NECs, it could have resulted in less-
ened Th2, mast cells and eosinophils responses 
and also reduced Orai1 expression in these cells.
    T-cell motility during TCR-mediated antigen rec-
ognition and formation of the immunological syn-
apse is regulated by SOCE (Delon et al., 1998; 
Bhakta et al., 2005), which plays an important role 
in the differentiation of naive CD4
+ T cells into Th2 
cells (Leitenberg and Bottomly, 1999). A sustained 
increase in intracellular Ca
2+ in the presence of 
costimulatory signals is necessary for a T cell to 
become activated and not unresponsive to future 
TCR stimulation (Borde et al., 2006; Bandyopadhyay 
et al., 2007). The expression of IL-4 was decreased 
in Th2 cells of Orai1-deficient mice (Gwack et al., 
2008). IL-4 can activate the transcription of germ-
line genes and accelerate the class switch re-
combination to IgE in local tissues (Fear et al., 
2004) through promoting the expression of cytidine 
deaminase, a protein normally expressed only in B 
cells in the germinal centers of lymphoid tissues 
(Muramatsu et al., 2000). Thus, when the IL-4 level 
is decreased, class switch recombination in local 
tissues is lessened and ovalbumin-specific IgE pro-
duction may be reduced. In fact, this is in agree-
ment with our findings in the nasal mucosa, serum, 
and the germinal centers of spleen. Therefore, it is 
logical to suggest that lessened SOCE may inhibit 
Th2 responses not only by inhibiting the activation 
of NECs but also by hampering the activation and 
proliferation of Th2 cells. The alteration of eosino-
phil function that we observed might be sub-
sequent to an impaired NECs and Th2 cells 
response. Interestingly, the ECP level in the NLF 
did not significantly change after treatment, even 
though its mRNA level in the nasal mucosa was 
reduced. This discrepancy needs further study, but 
it probably due to the ECP protein having a longer 
half-life than its mRNA. 
    In the absence of Orai1, B cells exhibited poor 
proliferation in response to BCR activation, sug-
gesting that Ca
2+ signals are essential for anti-
gen-dependent expansion of B cells in mice 
(Gwack et al., 2008) . While immunoglobulin levels 
were normal, Orai1-deficient patients failed to 
mount antigen-specific antibody responses. These 
past findings help explain our results that showed 
reduced levels of local and systemic OVA-IgE after 
lenti-ORAI1 administration and give further evi-
dence why the inhibition of Orai1 hindered allergic 
pathogenesis.
    From the indirect effects that stem from the in-
hibition of NEC secretion and Th2 responses, re-
duced Orai1 expression in the airway can also in-
hibit mast cell hypperreactivity. In mast cells, Ca
2+ 
signals were shown to be involved in FcεRI-medi-
ated degranulation and the release of histamine, 
leukotrienes, and prostaglandins (Baba et al., 2008; 
Vig et al., 2008), all of which in vitro are impaired in 
Orai1
-/- mice (Vig et al., 2008). Therefore, impaired 
expression of Orai1 in mast cells in the nasal mu-
cosa may partially account for the decrease in 
LTC4 production.
    In AR-LI mice, it was demonstrated that the local 
inhibition of Orai1 expression had effects on sys-
temic allergic responses, as there were reductions 
in inflammatory proteins in the serum and their cor-
responding mRNA transcripts in the spleen. This 
may be related to the circulation of the immune 
cells mentioned above, and suggests that local ad-
ministration of lenti-ORAI1 may partially block the 
immunopathological cascade of allergic reactions. 
    In summary, the present study was a preliminary 
in vivo investigation on how the downregulation of 
Orai1 expression in the airway by the admin-
istration of a siRNA-containing lentiviral vector 
would affect the local and systemic levels of sev-
eral allergy-related cytokines and OVA-IgE. The re-
sults suggested that inhibiting the function of CRAC 
channels in the airway might be a novel and effec-
tive therapy for AR. However, whether this treat-
ment can correct the Th1/Th2 imbalance in allergic 
disease for an extended time period and can work 
as a prophylactic measure are questions that re-
main to be answered. Further, it is not known if this 
intranasal transgenic therapy has the potential to 
completely eradicate the ability to mount an im-
mune response to pathogens in the airway. Further 
research should be done to answer these ques-
tions in the future to develop more targeted and 
lower risk therapeutic agents for AR.Orai1 expression and murine allergic rhinitis    187
Methods
shRNA template design and preparation
The interfering sequences that corresponded to the ORAI1 
gene were chosen from the mouse orai1 mRNA sequence 
(GenBank Accession No. NM_175423) with the use of the 
siRNA target finder and design tool available at 
http://www.ambion.com. BLASTN searches were con-
ducted on the sequence to ensure gene specificity. The se-
quences were designed to include a MluI restriction site, a 
21 nucleotide (nt) sense template (5'-TGAATCAGTCAT 
CGTCGCCAA-3'), a 9-nt loop (5'-TTCAAGAGA-3'), a 21 nt 
antisense template (5'-TTGGCGACGATGACTGATTCA- 
3'), a terminator sequence, and a ClaI restriction site. The 
sequences were chemically synthesized by Sangon 
(Shanghai, China).
Lentivirus production and determination of viral 
transfection efficacy and inhibition efficacy of Orai1 
transcription
The expression lentiviral vector pLVTHM (Tronolab, 
Lausanne, Switzerland) that carried the GFP reporter gene 
was restriction digested by the restriction enzymes MluI 
and ClaI (Takara, Japan) and gel purified. The synthesized 
shRNA sequences were also digested by the two enzymes 
and then inserted into the MluI-ClaI sites of the vector by 
T4 DNA ligase (Toyobo, Japan). The resultant clones were 
verified by sequencing.
        We cultured 293T cells (ATCC, Manassas, VA) in 
Dulbecco’s modified Eagle medium supplemented with 
10% fetal bovine serum (Invitrogen, Carlsbad, CA) in 5% 
CO2 at 37
oC. The recombinant lentiviruses were produced 
by the transient transfection of 293T cells. The 293T cells 
were seeded on 15-cm Petri dishes and were co-
transfected at 60-70% confluence with 20 μg of the inter-
ferential plasmid, 10 μg of the pRsv-REV plasmid, 15 μg of 
the pMDLg-pRRE plasmid, and 7.5 μg of the pMD2.G plas-
mid (Tronolab) according to standard protocols. Transfections 
were carried out with Lipofectamine 2000 (Invitrogen) as 
recommended by the manufacturer. The medium contain-
ing the recombinant lentivirus was changed once at 12 h 
and harvested at 72 h. This collected media was centri-
fuged at 4000 g at 4
oC for 10 min, the resulting super-
natant was centrifuged at 72000 g at 4
oC for 2 h, and the 
pellet was then resuspended in phosphate-buffered saline 
(PBS). Viral stocks were stored at -80
oC.
    To determine the viral transfection efficacy, PANC cells 
were plated on 6 cm dishes and infected with lenti-Orai1 
and lenti-GFP, which are lentiviral vectors without shRNA, 
respctively, and another 8 μg/ml of polybrene (Sigma-Aldrich, 
St. Louis, MO). Forty-eight h after the transduction, the 
cells were harvested, washed, and analyzed by FACS for 
GFP. 
    To  examine  the  efficacy  of  the  lenti-ORAI1 and len-
ti-GFP to inhibit the Orai1 transcription, the PANC cells 
which are untreated, infected with lenti-ORAI1, or infected 
with lenti-GFP were harvested and their total RNA was ex-
tracted with Trizol (Invitrogen). For reverse transcription, 2 
μg of the previously measured RNA was reverse tran-
scribed with first strand cDNA synthesis kits (Invitrogen) to 
complementary DNA according to the manufacturer's 
instructions. Primers were designed with Primer Express 
Software (Applied Biosystems, Foster City, CA) based on 
sequences available in GenBank and were synthesized 
(Sangon). Real-time RT-PCR was performed to detect the 
mRNA levels of Orai1. The primers were: forward primer 
5'-TTTGCCCTCATGATCAGCAC-3' and reverse primer 5'- 
TTGGCGACGATGACTGATTC-3'. Glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH) mRNA was examined to 
control for the sample-to-sample variation in RNA isolation 
and integrity by using the following pair of primers: forward 
primer 5'-ACCACAGTCCATGCCATCAC-3' and reverse 
primer 5'-TCCACCACCCTGTTGCTGTA-3'. Real-time PCR 
was performed on the ABI Prism 7500 Real-time PCR sys-
tem (Applied Biosystems) with the SYBR Premix Ex Taq kit 
(TaKaRa, Japan) in accordance with the manufacturer’s 
instructions. The specificity of the PCR products was eval-
uated by melting curve analysis. Evaluation of the data 
was performed by the cycle threshold (2
-ΔΔCT) method, and 
GAPDH was used for normalization. 
Animals
Female BALB/c mice (6-week old) were purchased from 
the Chinese Academy of Sciences Shanghai Laboratory 
Animal Center. The mice were maintained in horizontal 
laminar flow cabinets and were provided sterile food and 
water in a pathogen-free facility. All the animals were han-
dled in accordance with the National Institutes of Health 
Guidelines for the Care and Use of Laboratory Animals.
In vivo transfection protocols and determination of 
the kinetics of the inhibition efficacy of Orai1 
transcription 
For the lentiviral transfection, the BALB/c mice were an-
aesthetized with an intramuscular injection of xylazil (12 
μg/g body weight) and ketamine (40 μg/g) prior to the de-
livery of lysophosphatidylcholine (LPC; in PBS, 0.3% w/v; 
Sigma-Aldrich) to the nasal airway via inhalation-driven in-
stillation (8 μl/mouse). The lentivirus (1 × 10
9 tu/ml) were 
delivered into the nostrils of the mice (two 10-μl aliquots 
were administered to each mouse over a period of several 
min) 1 h after LPC delivery (Stocker et al., 2009). Twenty-one 
mice were randomly choosed, and eighteen of them were 
transfected with lenti-ORAI1 on Day 0. Three un-
transfected mice were sacrificed on day1. The transfected 
mice were sacrificed on day 1, day 3, day 7, day 14, day 
21, day 28, three mice each day. Their nasal mucosas 
were collected to mesure the mRNA levels of Orai1 in 
them using real-time RT-PCR.
Grouping, sensitization, challenge, and treatment 
protocol
Fifty-nine mice were randomly divided into five groups: nor-
mal control (n=15), normal mice with Lenti-Orai1 interfer-
enced (NLI) (n=7), AR (n=15), AR mice with lenti-GFP in-
terferenced (AR-GFP) (n=7), and AR mice with lenti-Orai1 
interferenced (AR-LI) (n=15).
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three of the groups of mice (AR, AR-GFP, and AR-LI) were 
sensitized to ovalbumin by the administration of 0.5 mg/ml 
ovalbumin (Grade V, Sigma-Aldrich) and 20 mg/ml alumi-
num hydroxide (Sigma-Aldrich) in saline by intraperitoneal 
injection at a dosage of 0.2 ml/mouse. The sensitization 
was repeated weekly for 3 weeks (day 1, 8 and 15), fol-
lowed by the daily delivery of an ovalbumin solution (40 
mg/ml in saline) into the nostrils via inhalation-driven in-
stillation (20 μl /mouse) on days 22-29 (the challenge). As 
controls, the remaining groups of mice received neither 
sensitization nor challenge, except for one dose of the 
challenge on day 29 (Figure 1). 
    On day 19, mice in NLI group, AR-GFP group, AR-LI 
group received transfection with lenti-ORAI1, lenti-GFP, 
and lenti-ORAI1 (1 × 10
9 tu/ml), respectively.
Examination of the transfected cells by the recombi-
nant lentivirus
To determine if the recombinant lentivirus was successfully 
transfected into cells in the nasal mucosas of the NLI, 
AR-GFP and AR-LI mice, three mice in each group were 
killed on day 22, and their nasal mucosa and spleens were 
carefully dissected. These tissues were fixed with 4% buf-
fered paraformaldehyde for 24 h, stained with DAPI and 
observed under fluorescence microscope to determine if 
the green fluorescence of GFP was expressed in poten-
tially transfected cells. 
Assessment of nasal symptoms, cellular analysis of 
NLF, and sample preparation
The nasal symptoms of each mouse were evaluated by 
counting the number of sneezes and episodes of nasal 
rubbing during the 10 min immediately after the last oval-
bumin intranasal challenge on day 29. Blood and NLF 
were collected from each mouse 2 h after the last 
challenge. One injection of 1 ml 0.01 M PBS was delivered 
into the nasal cavities of each mouse after sacrifice, and 
the fluid was collected with a tube below both nares (the 
NLF). The NLF and the coagulated blood were centrifuged, 
and the supernatants were analyzed by ELISA for levels of 
LTC4, ECP, OVA-IgE, and IL-4. 
    The cells in the NLF were resuspended with 1 ml 0.01 M 
PBS with 1% bovine serum albumin (BSA) for cellular 
analysis.The total cell number of leukocyte in the NLF 
samples was counted using an hemocytometer (Mindray 
3000, Shenzhen, China). The differential count of cells in 
NLF was determined by review of Wright-Giemsa stained 
smear and subclassification of 300 consecutive cells. By 
Wright-Giemsa staining, the percentages of epithelial cells, 
lymphocytes, neutrophils and eosinophils were determined.
    After the mice were sacrificed, the nasal mucosa and 
spleens of six mice in Normal, AR and LI group, and of four 
mice in NLI, AR-GFP group were obtained. These tissues 
were cut into two portions; one was dissected for isolation, 
the other for mRNA extraction. After sample preparation, 
all samples were frozen at -80
oC. 
    The heads and spleens of the remaining mice in Normal, 
AR and LI group were excised and immersed in 4% buf-
fered paraformaldehyde. After fixation, the heads were de-
calcified in 10% ethylenediamine tetraacetic acid for 28 
days. The specimens were embedded in paraffin and coro-
nally sectioned at a thickness of 4 μm. 
Western blotting analysis
The frozen tissues were homogenized, and the proteins in 
the tissues were extracted with Mouse/Rat Tissue Extract 
Protein Array Kit (Sigma-Aldrich). Protein homogenates 
(40 μg/lane) were separated by 12% SDS-PAGE gel and 
transferred to polyvinylidene difluoride membrane (Millipore, 
Billerica, MA). After 1 h blocking with 5% non-fat milk, the 
membrane was incubated with mouse anti-Orai1 mono-
clonal antibody (Sigma-Aldrich) at 4
oC overnight. The 
membrane was incubated with a secondary antibody con-
jugated to HRP (Jackson ImmnoResearch, West Grove, 
PA) and developed using chemiluminescence Western 
blotting system (Sigma-Aldrich). The expressions of IL-33, 
IL-17E and TSLP were also analyzed using rat anti-mouse 
IL-33 monoclonal antibody (R&D systems, Minneapolis, 
MN), rat anti-mouse IL-17E monoclonal antibody (R&D 
systems), and rabbit anti-mouse TSLP polyclonal antibody 
(ProSci Incorporated, Poway, CA), respectively. A mouse 
anti-β-actin monoclonal antibody (Sigma-Aldrich) was used 
to analyze the expression of β-actin, which was used as an 
internal control. 
Immunohistochemistry
For immunohistochemical staining, slices were deparaffi-
nized and rehydrated with distilled water. Endogenous per-
oxidase was blocked with 3% hydrogen peroxide for 20 
min. Normal horse serum (Vector Lab, Burlingame, CA) 
was used to block non-specific binding, and a previously 
optimized concentration of mouse anti-Orai1 monoclonal 
antibody (Sigma-Aldrich) in antibody diluent (Dako, Via Real 
Carpinteria, CA) was immediately applied to the sections 
and incubated for 1 h at room temperature and overnight at 
4
oC. Biotinylated anti-mouse IgG secondary antibody 
(Vector Lab) was applied to each section for 30 min, fol-
lowed by 20 min incubation with horseradish peroxidase 
streptavidin (Vector Lab). Slides were stained with 3,3-dia-
minobenzidine chromogene (Sigma-Aldrich) for 3 min and 
counterstained with hematoxylin. Antibody localization was 
detected microscopically by brown staining. Immunoreac-
tivity and the cellular distribution of Orai1 were assessed 
under light microscopy by two observers who were blinded 
to the sample groups.
ELISA
Concentrations of OVA-IgE, LTC4, ECP, and IL-4 in serum 
and NLF were measured by the corresponding ELISA kits 
(Blue Gene, Shanghai, China). The ELISAs were per-
formed in accordance with the manufacturer’s protocols.
Real-time reverse transcription PCR (real-time 
RT-PCR)
Total RNA was extracted from the nasal mucosa and 
spleen samples with Trizol (Invitrogen). Real-time RT-PCR 
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EAR3, the germline Cε transcript, and IL-4, using the 
method mentioned before. The primers were as follows: 
LTC4S, forward primer 5’-CCTACAGGTGATCTCTGCACG 
A-3’ and reverse primer 5’-TATCCCTGGAAATAGCGGAG 
G-3’; EAR3, forward primer 5’-TAATGCTTGCCTCATGCCT 
G-3’ and reverse primer 5’-TGCACAAGCCACTTGGATTT-3’; 
Germline Cε transcript, forward primer 5’-TGCATTGAAGG 
CTACGGCTA-3’ and reverse primer 5’-TTGGAGCCATTG 
GATTTCAG-3’; IL-4, forward primer 5’-ATCGGCATTTTGA 
ACGAGGT-3’ and reverse primer 5’-TCGAAAAGCCCGA 
AAGAGTC-3’. GAPDH mRNA was examined to control for 
the sample-to-sample variation in RNA isolation and 
integrity. Evaluation of the data was performed by the cycle 
threshold (2
-ΔΔCT) method, and GAPDH was used for 
normalization. 
Statistical analysis
We used the unpaired Student’s t test ± Welch’s correc-
tion to compare sneezes, episodes of nasal rubbing, the 
expression levels of Orai1, inflammatory cells in the NLF, 
inflammatory cytokine levels, and OVA-IgE levels between 
the three groups (normal, AR, and LI). Statistical analysis 
was performed using commercially available statistical 
software SPSS 17.0 (SPSS, Chicago, IL). Data are pre-
sented as mean ± standard error of the mean (SEM). P 
values of ＜ 0.05 were considered to be statistically 
significant.
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